213 related articles for article (PubMed ID: 24725695)
1. Pretreatment growth rate predicts radiation response in vestibular schwannomas.
Niu NN; Niemierko A; Larvie M; Curtin H; Loeffler JS; McKenna MJ; Shih HA
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):113-9. PubMed ID: 24725695
[TBL] [Abstract][Full Text] [Related]
2. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
3. Volume changes after stereotactic LINAC radiotherapy in vestibular schwannoma: control rate and growth patterns.
van de Langenberg R; Dohmen AJ; de Bondt BJ; Nelemans PJ; Baumert BG; Stokroos RJ
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):343-9. PubMed ID: 22361083
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated stereotactic radiation therapy in three to five fractions for vestibular schwannoma.
Morimoto M; Yoshioka Y; Kotsuma T; Adachi K; Shiomi H; Suzuki O; Seo Y; Koizumi M; Kagawa N; Kinoshita M; Hashimoto N; Ogawa K
Jpn J Clin Oncol; 2013 Aug; 43(8):805-12. PubMed ID: 23780990
[TBL] [Abstract][Full Text] [Related]
5. Radiosurgery in patients with bilateral vestibular schwannomas.
Vachhani JA; Friedman WA
Stereotact Funct Neurosurg; 2007; 85(6):273-8. PubMed ID: 17709979
[TBL] [Abstract][Full Text] [Related]
6. Linear accelerator radiosurgery for treatment of vestibular schwannomas in neurofibromatosis 2.
Kuo YH; Roos D; Brophy BP
J Clin Neurosci; 2008 Jul; 15(7):744-8. PubMed ID: 18403208
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic outcomes in relation to tumor expansion after fractionated stereotactic radiation therapy for vestibular schwannomas: single-institutional long-term experience.
Aoyama H; Onodera S; Takeichi N; Onimaru R; Terasaka S; Sawamura Y; Shirato H
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):329-34. PubMed ID: 22704983
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2.
Subach BR; Kondziolka D; Lunsford LD; Bissonette DJ; Flickinger JC; Maitz AH
J Neurosurg; 1999 May; 90(5):815-22. PubMed ID: 10223445
[TBL] [Abstract][Full Text] [Related]
9. Experience with Novalis stereotactic radiosurgery for vestibular schwannomas.
Lo WL; Yang KY; Huang YJ; Chen WF; Liao CC; Huang YH
Clin Neurol Neurosurg; 2014 Jun; 121():30-4. PubMed ID: 24793471
[TBL] [Abstract][Full Text] [Related]
10. Hearing outcomes after stereotactic radiosurgery for unilateral intracanalicular vestibular schwannomas: implication of transient volume expansion.
Kim YH; Kim DG; Han JH; Chung HT; Kim IK; Song SW; Park JH; Kim JW; Kim YH; Park CK; Kim CY; Paek SH; Jung HW
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):61-7. PubMed ID: 22580122
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates.
Mathieu D; Kondziolka D; Flickinger JC; Niranjan A; Williamson R; Martin JJ; Lunsford LD
Neurosurgery; 2007 Mar; 60(3):460-8; discussion 468-70. PubMed ID: 17327790
[TBL] [Abstract][Full Text] [Related]
12. Low-dose radiosurgery for large vestibular schwannomas: long-term results of functional preservation.
Inoue HK
J Neurosurg; 2005 Jan; 102 Suppl():111-3. PubMed ID: 15662791
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity.
Chan AW; Black P; Ojemann RG; Barker FG; Kooy HM; Lopes VV; McKenna MJ; Shrieve DC; Martuza RL; Loeffler JS
Neurosurgery; 2005 Jul; 57(1):60-70; discussion 60-70. PubMed ID: 15987541
[TBL] [Abstract][Full Text] [Related]
14. Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration.
Picry A; Bonne NX; Ding J; Aboukais R; Lejeune JP; Baroncini M; Dubrulle F; Vincent C
Laryngoscope; 2016 Oct; 126(10):2358-62. PubMed ID: 27075822
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tumor expansion after stereotactic radiosurgery in patients harboring vestibular schwannomas.
Hasegawa T; Kida Y; Yoshimoto M; Koike J; Goto K
Neurosurgery; 2006 Jun; 58(6):1119-28; discussion 1119-28. PubMed ID: 16723891
[TBL] [Abstract][Full Text] [Related]
17. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.
Baser ME; Makariou EV; Parry DM
J Neurosurg; 2002 Feb; 96(2):217-22. PubMed ID: 11838793
[TBL] [Abstract][Full Text] [Related]
18. Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation.
Phi JH; Kim DG; Chung HT; Lee J; Paek SH; Jung HW
Cancer; 2009 Jan; 115(2):390-8. PubMed ID: 19109818
[TBL] [Abstract][Full Text] [Related]
19. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
20. Follow-up after gamma knife radiosurgery for vestibular schwannomas: volumetric and axial control rates.
Timmer FC; Hanssens PE; van Haren AE; van Overbeeke JJ; Mulder JJ; Cremers CW; Graamans K
Laryngoscope; 2011 Jul; 121(7):1359-66. PubMed ID: 21647893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
